<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361699</url>
  </required_header>
  <id_info>
    <org_study_id>J-STARS hsCRP</org_study_id>
    <secondary_id>C000000211</secondary_id>
    <nct_id>NCT00361699</nct_id>
  </id_info>
  <brief_title>hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)</brief_title>
  <official_title>Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon the Serum High Sensitive CRP in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <brief_summary>
    <textblock>
      Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in
      preventing recurrent vascular events from ischemic heart disease patients, whose mechanism
      consists in not only the reduction of serum lipid level but also anti-inflammatory effects.
      Serum high sensitive CRP is known to be a predictor of cardiovascular events independent of
      other conventional risk factors. The present substudy examine whether such pleiotrophic
      effect of HMG-CoA reductase inhibitor (statin) which decreases high sensitive CRP would be
      observed in the post-ischemic stroke patients who have already been registered in the
      J-STARS, and the relationship the values of high sensitive CRP and recurrence of stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum level of high sensitive CRP</measure>
    <time_frame>until the last day of the next February after 5-year follow-up survey</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrent stroke</measure>
    <time_frame>until the last day of the next February after 5-year follow-up survey</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1095</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient has no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset

          -  Hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription of
             statin within previous 30 days

          -  Able to visit outpatient department

          -  Informed consent on the form filled in by the patient.

        Exclusion Criteria:

          -  Ischemic stroke of other determined cause according to the TOAST classification

          -  Ischemic heart disease and necessary to use statin

          -  Hemorrhagic disorders

          -  Platelet count &lt;=100,000/ul within 3 months prior to study start

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&gt;= 100IU/L within 3
             months prior to study start

          -  Serum creatinine &gt;=2.0mg/dl within 3 months prior to study start

          -  A scheduled operation

          -  The presence of malignant disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masayasu Matsumoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroashima</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://jstars.umin.ne.jp</url>
    <description>Available only in Japanese</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2006</study_first_submitted>
  <study_first_submitted_qc>August 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2006</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>brain ischemia</keyword>
  <keyword>cerebrovascular accident</keyword>
  <keyword>statin</keyword>
  <keyword>hydroxymethylglutaryl-CoA reductase inhibitors</keyword>
  <keyword>cholesterol</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>multicenter studies</keyword>
  <keyword>prospective studies</keyword>
  <keyword>endpoint determination</keyword>
  <keyword>randomized controlled trials</keyword>
  <keyword>recurrence</keyword>
  <keyword>pravastatin</keyword>
  <keyword>c-reactive Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

